Analyst ratings can significantly influence investor sentiment and stock prices. A downgrade to Peer Perform implies that Wolfe Research sees RAPT Therapeutics as performing in line with its peers, rather than outperforming them. This could lead to a neutral short-term impact on the stock as investors reassess their expectations based on this new rating.